SHANGHAI & NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Zhejiang Hisun Pharmaceuticals (SSE stock code 600267), a leading pharmaceutical company in China, today jointly announced the signing of a memorandum of understanding (MOU) on their intention to establish a joint venture. This potential partnership would aim to strengthen the ability of both companies to reach more patients with high-quality and low-cost medicines in the branded generics arena. Under the MOU, the two companies wi

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the European Medicines Agency (EMA) has accepted Pfizer’s filing for regulatory review of axitinib for patients with advanced renal cell carcinoma (RCC) after failure of prior systemic treatment. This submission was based on Phase 3 data from the AXIS 1032 trial. Pfizer will present full results from this trial, as well as additional data on axitinib, at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO), being

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Mace Rothenberg, Senior Vice President, Clinical Development and Medical Affairs, Oncology Business Unit, at the Goldman Sachs 32nd Annual Global Healthcare Conference on Tuesday, June 7, 2011 at 3:30 p.m. Pacific Daylight Saving Time. To listen to the webcast, visit our web site at www.pfizer.com and click on the “Goldman Sachs 32nd Annual Global Healthcare Conference” lin

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Pfizer’s oncology leadership team at an analyst and investor meeting on Monday, June 6, 2011 at 6:00 p.m. Central Daylight Saving Time, in connection with the annual meeting of the American Society of Clinical Oncology (ASCO). To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “Pfizer Analyst and Investor Meeting at ASCO” link

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced strategic partnerships with ICON plc and PAREXEL International Corporation, both of which will serve as strategic providers of clinical trial implementation services over a five-year period beginning in June 2011. The new partnerships will be fully implemented over an 18-to-24 month period. The ICON and PAREXEL alliances reflect Pfizer’s recent commitment to strengthen the performance of its innovative core. Pfizer announced in February a co

THOUSAND OAKS, Calif. and NEW YORK--(BUSINESS WIRE)--Amgen (Nasdaq: AMGN) and Pfizer Inc. (NYSE: PFE) today announced new results from multiple studies of ENBREL, further expanding the body of evidence supporting the efficacy and safety profile of ENBREL, the most prescribed biologic by rheumatologists in the United States (U.S.). Eighteen abstracts across four indications, including moderate-to-severe rheumatoid arthritis (RA), ankylosing spondylitis (AS), moderate-to-severe plaque psoriasis (P

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced data from ORAL Sync (A3921046) and Study A3921109, two clinical trials of tofacitinib (development code: CP-690,550), an investigational, novel, oral JAK inhibitor, being studied in rheumatoid arthritis (RA). Top-line results of ORAL Sync, a pivotal Phase 3 trial, were announced earlier this year. A separate trial, Study A3921109, evaluated the safety and efficacy of atorvastatin versus placebo in reducing LDL cholesterol (LDL-C)

GOTHENBURG, Sweden--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced results from a pre-specified sub-analysis1 of the EMPHASIS-HF trial2 which showed that Inspra® (eplerenone), added to standard recommended therapy, statistically significantly reduced the incidence of new onset atrial fibrillation or flutter (AF/F) in patients with systolic heart failure and mild symptoms, compared with placebo plus standard therapy. This analysis was a pre-specified secondary endpoint in the EMPHASIS-H

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SUTENT® (sunitinib malate) as the first anti-VEGF therapy to treat progressive, well-differentiated pancreatic neuroendocrine tumors (NET) in patients with unresectable locally advanced or metastatic disease. Pancreatic NET is a rare cancer reported in two to four people per million annually worldwide.1,2 “We are delighted that SUTENT has been granted approval by the FDA as an eff

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--The European Commission has approved ELIQUIS® in the 27 countries of the European Union (EU) for the prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. This decision marks the first approval for ELIQUIS®, a new oral direct Factor Xa inhibitor being developed by the alliance of Bristol-Myers Squibb Company and Pfizer Inc. “Major orthopedic surgery, such as total knee replaceme